GLIAGEN LLC, DEVELOPER OF TECHNOLOGIES USED TO TREAT NEURODEGENERATIVE DISEASES
GliaGen is focused on the development of novel diagnostic and therapeutic technologies specifically tailored to treat neurodegenerative diseases.
GliaGen is developing novel treatments for neuroaffective disorders including Multiple Sclerosis, Alzheimers, and Parkinsons; including neurotrauma such as spinal cord injuries.
The Quincy, Mass.-
In addition to commercializing the patent pending technology, the WSU spinoff will also support further research at Wayne State.
GliaGen currently employs five people. For more information visit: http://www.gliagen.com
Home | Calendar | Campus Map
Center for Molecular Medicine and Genetics • Wayne State University School of Medicine
• 3127 Scott Hall • 540 East Canfield • Detroit, MI 48201. Administrative Office:
(313) 577-
GLYTAG, LLC, INNOVATIVE DRUG TARGETING SYSTEM FINDS NEW WAY TO FIGHT CANCER
GlyTag has developed a novel drug targeting system that increases a drug’s therapeutic
efficacy while reducing its toxicity to non-
The GlyTag system takes advantage of one of nature’s own methods of targeting growth
factors to specific cells in the body through unique cell surface heparin-
A “GlyTag” is a polypeptide sequence specifically designed to target recombinant proteins or other macromolecules to specific cells in the body.
GlyTag is currently completing pre-
